Peapod Lane Capital LLC Acquires New Stake in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)

Peapod Lane Capital LLC purchased a new position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 558,418 shares of the company's stock, valued at approximately $888,000. Peapod Lane Capital LLC owned approximately 0.78% of Zentalis Pharmaceuticals at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in the stock. Voya Investment Management LLC grew its position in Zentalis Pharmaceuticals by 14.1% in the fourth quarter. Voya Investment Management LLC now owns 57,017 shares of the company's stock worth $173,000 after acquiring an additional 7,058 shares in the last quarter. Wells Fargo & Company MN boosted its holdings in shares of Zentalis Pharmaceuticals by 26.8% in the 4th quarter. Wells Fargo & Company MN now owns 34,609 shares of the company's stock worth $105,000 after purchasing an additional 7,305 shares in the last quarter. Corton Capital Inc. bought a new position in shares of Zentalis Pharmaceuticals during the 4th quarter valued at about $32,000. Northern Trust Corp raised its holdings in shares of Zentalis Pharmaceuticals by 2.2% during the 4th quarter. Northern Trust Corp now owns 484,738 shares of the company's stock valued at $1,469,000 after buying an additional 10,513 shares in the last quarter. Finally, Federated Hermes Inc. lifted its holdings in shares of Zentalis Pharmaceuticals by 2.2% in the 4th quarter. Federated Hermes Inc. now owns 493,982 shares of the company's stock worth $1,497,000 after acquiring an additional 10,644 shares during the last quarter.

Zentalis Pharmaceuticals Price Performance

Zentalis Pharmaceuticals stock traded down $0.04 during trading hours on Friday, reaching $1.33. The stock had a trading volume of 623,162 shares, compared to its average volume of 1,447,645. The company has a fifty day simple moving average of $1.31 and a 200-day simple moving average of $1.73. Zentalis Pharmaceuticals, Inc. has a 52 week low of $1.01 and a 52 week high of $5.44. The stock has a market cap of $95.69 million, a PE ratio of -0.42 and a beta of 1.59.

Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) last posted its earnings results on Wednesday, May 14th. The company reported ($0.67) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.67). Research analysts predict that Zentalis Pharmaceuticals, Inc. will post -2.42 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the stock. Wedbush reiterated a "neutral" rating and issued a $4.00 target price on shares of Zentalis Pharmaceuticals in a research report on Thursday, May 15th. HC Wainwright reissued a "buy" rating and issued a $10.00 target price on shares of Zentalis Pharmaceuticals in a research note on Thursday, May 15th. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $8.37.

Insider Buying and Selling at Zentalis Pharmaceuticals

In other Zentalis Pharmaceuticals news, Director Scott Dunseth Myers bought 21,000 shares of the firm's stock in a transaction that occurred on Wednesday, April 30th. The stock was bought at an average price of $1.40 per share, for a total transaction of $29,400.00. Following the completion of the acquisition, the director directly owned 281,192 shares in the company, valued at $393,668.80. The trade was a 8.07% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 1.90% of the company's stock.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.